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especially in patients pretreated with 
(chemo)radiotherapy.1,2
In this case, there seems to be a 
relationship between fistula formation 
and EUS. The high C-reactive protein, 
normalizing during antibiotic treatment, 
suggests an infectious component.
Normally, EUS-FNA is a safe 
technique but infectious mediastinitis 
in necrotic lymph nodes, resulting in 
cavitation, was reported previously.3
In our patient, optimal circum-
stances for fistula formation were created 
in the aspirated node by pretreatment 
with bevacizumab. repeated needle 
passes in necrotic tissue caused longitu-
dinal fissures. Delayed wound-healing 
and secondary infection resulted in fis-
tula formation finally.
EUS-FNA is therefore not recom-
mended in patients on treatment with 
bevacizumab. If EUS-FNA is nonethe-
less indicated, antibiotic prophylaxis is 
advisable.
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To the Editor:
I read with interest the article 
“highly Sensitive Detection of EGFR 
T790M Mutation Using Colony 
hybridization Predicts Favorable 
Prognosis of Patients with Lung Cancer 
harboring Activating EGFR Mutation” 
by Fujita et al.1 published in November 
2012 in this journal. The authors, using a 
highly sensitive methodology, detect, in 
pretyrosine kinase inhibitor (TKI) speci-
mens, a rate of EGFR T790M mutations 
of 79%, much higher than the rate of 0% 
to 35%, which was previously reported.2,3 
In addition, with a 0.5% cutoff of T790M 
pretreatment alleles, they find an asso-
ciation with favorable outcome. They 
suggest that the abundance of T790M 
mutated cells, and not their mere pres-
ence, is correlated with a better progno-
sis after TKI treatment. The biological 
paradox concerning how tumors carry-
ing two EGFR mutations with synergis-
tic oncogenic potential acquire slower 
growth kinetics, remains unexplained. 
Given the issue of tumor heterogeneity 
different scenarios can be speculated: 
(1), activating and resistant mutation 
in cis on the same allele, (2), in trans 
on different alleles and (3), in different 
clones. The first situation (Fig.1A), after 
TKI therapy, would lead to a decrease 
of sensitive target cells with an enrich-
ment of resistant double-mutated cells 
that, based on current biological evi-
dence, should be equipped with higher 
growth potential. In the second scenario 
(Fig.1B), tumor behavior would be dif-
ficult to anticipate, depending on which 
allele is expressed within the cells. The 
sensitive allele, however, should be 
preferentially expressed leading to an 
initial decrease of cells with the activat-
ing mutation and an increase of double-
mutated cells whose growth behavior, 
with the present knowledge, is unknown. 
In the last scenario (Fig.1C), where the 
mutations are present in different clones, 
selective drug pressure would be applied 
only on target cells with the activat-
ing mutation whereas the clones with 
the resistant T790M mutation would be 
advantaged to grow under drug pressure. 
This latter scenario could explain the 
more indolent behavior seen in patients 
with a pretreatment T790M mutation 
because the resistance mutation has been 
proven to be less oncogenic both in vitro 
and in vivo. The knowledge regarding 
the in cis or in trans position of the sen-
sitive and resistance mutations is cur-
rently scarce, and both possibilities have 
been reported. Kobayashi et al.4 with 
subcloning experiments found T790M 
mutations associated with both, exon 19 
deletions and wild-type sequences, sug-
gesting a monoallelic situation (in cis), 
possibly concomitant with a biallelic 
situation (in trans), or with the presence 
of distinct population of cells. Miyazawa 
et al.5 on the contrary, found only clones 
with single activating mutations or 
with both activating and resistant muta-
tions (in cis). In conclusion, the current 
knowledge on the evolution of resistance 
mutations is still scarce and, given the 
major clinical implications for the con-
tinous successful treatment Wof non–
small-cell lung cancer patients, deserves 
further study.
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FIGURE1.  Putative scenarios of tumor evolution after TKI therapy. Black circles, 
cells with EGFR activating mutation; red circles, cells with activating or resistant 
mutation; Black lines, different alleles; black arrowhead, activating mutation; red 
arrowhead, resistant mutation. TKI, tyrosine kinase inhibitor.
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To the Editor:
We read with interest a recent 
article by Nakamura et al.1 regarding 
noninvasive system for monitoring 
resistance to epidermal growth fac-
tor receptor (EGFr)-tyrosine kinase 
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Does T790M 
Disappear? Successful 
Gefitinib Rechallenge 
After T790M 
Disappearance in a 
Patient With EGFR-
Mutant Non–Small-Cell 
Lung Cancer
inhibitors (TKIs) with plasma DNA. 
They showed a case with EGFR-mutant 
non–small-cell lung cancer in which the 
T790M-resistant mutation disappear 
after TKI-free interval with cytotoxic 
chemotherapy. We herein demonstrate 
a case with EGFR-mutant non–small-
cell lung cancer, where gefitinib rechal-
lenge was effective after disappearance 
of T790M.
A 66-year-old man having multi-
ple pulmonary nodules was referred to 
our institution. We performed a biopsy 
of the primary mass and diagnosed the 
patient as stage IV lung adenocarci-
noma. Irinotecan + S-1 and cisplatin 
+ docetaxel were sequentially admin-
istered. After these chemotherapies, 
EGFR mutation analysis became com-
mercially available. We examined the 
initial biopsy specimen using the pep-
tide nucleic acid-locked nucleic acid 
PCr clamp method; exon 19 deletional 
mutation and exon 21 L858r point 
mutation were detected. We therefore 
administered gefitinib as the third-line 
therapy. Partial response (Pr) was 
obtained, but the primary tumor pro-
gressed after 2 years. We performed 
a rebiopsy and L858r + T790M was 
revealed. We then administered cispla-
tin + S-1. Pr was obtained, but progres-
sion was confirmed after 1 year. We 
performed a second biopsy for the third 
time on the same tumor and detected 
only L858r; T790M had seemingly 
disappeared. Gefitinib was therefore 
rechallenged, and Pr was achieved (Fig. 
1A and 1B). Six months later, the pri-
mary tumor progressed again (Fig. 1C). 
We did a third rebiopsy and detected 
L858r + T790M again. Despite the 
detection of T790M, we have contin-
ued gefitinib beyond the progression, 
expecting an indolent course.
Did the T790M really disap-
pear in our present case? Chmielecki 
